Pharmacogenetics and personalized treatment of type 2 diabetes mellitus

Autores
Yang, Pablo; Ojeda Heredia, Norma Veronica; Beltramo, Dante Miguel; Soria, Néstor Walter
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases in the world. An important difference in effectiveness and toxicity of hypoglycemic agents has been associated with the presence of genetic variants in people with T2DM. We conducted a literature review up November 2015 by combining keywords type 2 diabetes mellitus, hypoglycemic agents and pharmacogenetics (PKG). Metformin, sulfonylureas, and meglitinide drugs are widely used for the T2DM treatment, although new drugs in combination with metformin are administered. Genetic variants in proteins that function as carriers, channels, or metabolizing enzymes affect both the pharmacokinetics and pharmacodynamics of these agents. Significant progress in T2DM’s pharmacogenetics has been made; however, more studies involving a larger number of patients from different ethnic groups must be done. Furthermore, patients with T2DM generally are complex patients receiving hypolipidemic and hypotensive medications. Drug-drug interaction studies between these drugs must be done to really know the contribution of each polymorphism in drug effectiveness and/or toxicity.
Fil: Yang, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Universidad Católica de Córdoba. Facultad de Ciencias Químicas; Argentina
Fil: Ojeda Heredia, Norma Veronica. Hospital Nacional de Clínicas. Servicio de Diabetología; Argentina
Fil: Beltramo, Dante Miguel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Universidad Católica de Córdoba. Facultad de Ciencias Químicas; Argentina
Fil: Soria, Néstor Walter. Universidad Católica de Córdoba. Facultad de Ciencias Químicas; Argentina
Materia
EFFECTIVENESS
HYPOGLYCEMIC AGENTS
POLYMORPHISMS
TOXICITY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/180069
Acceder
id CONICETDig_f113dd37084a6a9772ebc86247d18e0b
oai_identifier_str oai:ri.conicet.gov.ar:11336/180069
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Pharmacogenetics and personalized treatment of type 2 diabetes mellitusYang, PabloOjeda Heredia, Norma VeronicaBeltramo, Dante MiguelSoria, Néstor WalterEFFECTIVENESSHYPOGLYCEMIC AGENTSPOLYMORPHISMSTOXICITYhttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases in the world. An important difference in effectiveness and toxicity of hypoglycemic agents has been associated with the presence of genetic variants in people with T2DM. We conducted a literature review up November 2015 by combining keywords type 2 diabetes mellitus, hypoglycemic agents and pharmacogenetics (PKG). Metformin, sulfonylureas, and meglitinide drugs are widely used for the T2DM treatment, although new drugs in combination with metformin are administered. Genetic variants in proteins that function as carriers, channels, or metabolizing enzymes affect both the pharmacokinetics and pharmacodynamics of these agents. Significant progress in T2DM’s pharmacogenetics has been made; however, more studies involving a larger number of patients from different ethnic groups must be done. Furthermore, patients with T2DM generally are complex patients receiving hypolipidemic and hypotensive medications. Drug-drug interaction studies between these drugs must be done to really know the contribution of each polymorphism in drug effectiveness and/or toxicity.Fil: Yang, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Universidad Católica de Córdoba. Facultad de Ciencias Químicas; ArgentinaFil: Ojeda Heredia, Norma Veronica. Hospital Nacional de Clínicas. Servicio de Diabetología; ArgentinaFil: Beltramo, Dante Miguel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Universidad Católica de Córdoba. Facultad de Ciencias Químicas; ArgentinaFil: Soria, Néstor Walter. Universidad Católica de Córdoba. Facultad de Ciencias Químicas; ArgentinaMedknow Publications2016-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/180069Yang, Pablo; Ojeda Heredia, Norma Veronica; Beltramo, Dante Miguel; Soria, Néstor Walter; Pharmacogenetics and personalized treatment of type 2 diabetes mellitus; Medknow Publications; International Journal Of Diabetes In Developing Countries; 36; 4; 8-2016; 508-5180973-3930CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s13410-016-0517-2info:eu-repo/semantics/altIdentifier/doi/10.1007/s13410-016-0517-2info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:47:08Zoai:ri.conicet.gov.ar:11336/180069instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:47:09.256CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
title Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
spellingShingle Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
Yang, Pablo
EFFECTIVENESS
HYPOGLYCEMIC AGENTS
POLYMORPHISMS
TOXICITY
title_short Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
title_full Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
title_fullStr Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
title_full_unstemmed Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
title_sort Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
dc.creator.none.fl_str_mv Yang, Pablo
Ojeda Heredia, Norma Veronica
Beltramo, Dante Miguel
Soria, Néstor Walter
author Yang, Pablo
author_facet Yang, Pablo
Ojeda Heredia, Norma Veronica
Beltramo, Dante Miguel
Soria, Néstor Walter
author_role author
author2 Ojeda Heredia, Norma Veronica
Beltramo, Dante Miguel
Soria, Néstor Walter
author2_role author
author
author
dc.subject.none.fl_str_mv EFFECTIVENESS
HYPOGLYCEMIC AGENTS
POLYMORPHISMS
TOXICITY
topic EFFECTIVENESS
HYPOGLYCEMIC AGENTS
POLYMORPHISMS
TOXICITY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases in the world. An important difference in effectiveness and toxicity of hypoglycemic agents has been associated with the presence of genetic variants in people with T2DM. We conducted a literature review up November 2015 by combining keywords type 2 diabetes mellitus, hypoglycemic agents and pharmacogenetics (PKG). Metformin, sulfonylureas, and meglitinide drugs are widely used for the T2DM treatment, although new drugs in combination with metformin are administered. Genetic variants in proteins that function as carriers, channels, or metabolizing enzymes affect both the pharmacokinetics and pharmacodynamics of these agents. Significant progress in T2DM’s pharmacogenetics has been made; however, more studies involving a larger number of patients from different ethnic groups must be done. Furthermore, patients with T2DM generally are complex patients receiving hypolipidemic and hypotensive medications. Drug-drug interaction studies between these drugs must be done to really know the contribution of each polymorphism in drug effectiveness and/or toxicity.
Fil: Yang, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Universidad Católica de Córdoba. Facultad de Ciencias Químicas; Argentina
Fil: Ojeda Heredia, Norma Veronica. Hospital Nacional de Clínicas. Servicio de Diabetología; Argentina
Fil: Beltramo, Dante Miguel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Universidad Católica de Córdoba. Facultad de Ciencias Químicas; Argentina
Fil: Soria, Néstor Walter. Universidad Católica de Córdoba. Facultad de Ciencias Químicas; Argentina
description Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases in the world. An important difference in effectiveness and toxicity of hypoglycemic agents has been associated with the presence of genetic variants in people with T2DM. We conducted a literature review up November 2015 by combining keywords type 2 diabetes mellitus, hypoglycemic agents and pharmacogenetics (PKG). Metformin, sulfonylureas, and meglitinide drugs are widely used for the T2DM treatment, although new drugs in combination with metformin are administered. Genetic variants in proteins that function as carriers, channels, or metabolizing enzymes affect both the pharmacokinetics and pharmacodynamics of these agents. Significant progress in T2DM’s pharmacogenetics has been made; however, more studies involving a larger number of patients from different ethnic groups must be done. Furthermore, patients with T2DM generally are complex patients receiving hypolipidemic and hypotensive medications. Drug-drug interaction studies between these drugs must be done to really know the contribution of each polymorphism in drug effectiveness and/or toxicity.
publishDate 2016
dc.date.none.fl_str_mv 2016-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/180069
Yang, Pablo; Ojeda Heredia, Norma Veronica; Beltramo, Dante Miguel; Soria, Néstor Walter; Pharmacogenetics and personalized treatment of type 2 diabetes mellitus; Medknow Publications; International Journal Of Diabetes In Developing Countries; 36; 4; 8-2016; 508-518
0973-3930
CONICET Digital
CONICET
url http://hdl.handle.net/11336/180069
identifier_str_mv Yang, Pablo; Ojeda Heredia, Norma Veronica; Beltramo, Dante Miguel; Soria, Néstor Walter; Pharmacogenetics and personalized treatment of type 2 diabetes mellitus; Medknow Publications; International Journal Of Diabetes In Developing Countries; 36; 4; 8-2016; 508-518
0973-3930
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s13410-016-0517-2
info:eu-repo/semantics/altIdentifier/doi/10.1007/s13410-016-0517-2
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Medknow Publications
publisher.none.fl_str_mv Medknow Publications
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082986425974784
score 13.22299

Publicaciones similares